Voluntary Recall of Seasource Detox Spa® Foaming Sea Salt Scrub by Arbonne International, LLC
September 14, 2009
On September 3rd, Arbonne International, LLC ("Arbonne") voluntarily recalled one lot of its Seasource Detox Spa® Foaming Sea Salt Scrub after the company discovered the presence of Pseudomonas aeruginosa in the recalled lot. The recalled products were manufactured by a third party and distributed nationwide through Arbonne Independent Consultants.
The product comes in a 6.8 fluid oz white tube and is identified with a lot number on the crimping at the top of the tube. The Seasource Detox Spa® Foaming Sea Salt Scrub products affected by this voluntary recall are ONLY from the following lot number (with shipping dates ranging from March 28, 2008 to July 15, 2009): Z928
This voluntary recall was initiated by Arbonne as a result of discovering the presence of Pseudomonas aeruginosa bacteria in the recalled lot. No other lots are affected.
The organism Pseudomonas aeruginosa may cause dermatitis, soft tissue infections, bacteremia, and a variety of system infections, particularly with users who are immunosuppressed. Because the Foaming Sea Salt Scrub is used to exfoliate the skin’s surface, there is a possibility that inadvertent introduction of the tainted product directly into any skin abrasions could result in infection.
No illnesses have been reported in connection with this product.
Purchasers of the recalled product lot are advised not to use it. Arbonne will, at the purchaser's choice, replace or exchange the product or refund money paid for the recalled product. In order to replace or exchange product or receive a refund, Arbonne is requesting purchasers of the recalled product lot to contact Arbonne at 1-800-ARBONNE between the hours of 6:00 a.m. and 6:00 p.m. Pacific Time weekdays and between the hours of 6:00 a.m. and 3:00 p.m. Pacific Time on Saturdays, and have the product with the recalled lot number available to return to Arbonne in order to complete the transaction.
This voluntary recall was initiated by Arbonne and is being conducted with the knowledge of the U.S. Food and Drug Administration.